ANGIOCHEM TO PRESENT POSITIVE CNS and peripheral anti-tumor activity of …

ANGIOCHEM TO PRESENT POSITIVE CNS and peripheral anti-tumor activity of …

Montreal, Canada, May 30, 2014 – Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the bloodbrain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, …

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.